Navigation Links
BioMarin Announces Third Quarter 2010 Financial Results
Date:10/28/2010

10, the calculation of GAAP diluted earnings per share includes the 26.3 million shares related to the outstanding convertible debt.  The remaining periods presented excludes the 26.3 million shares related to the outstanding convertible debt from the calculation of GAAP diluted earnings per share as their impact is considered anti-dilutive.  

The calculation of non-GAAP diluted earnings per share for the third quarter and first nine months of 2009 include 16.0 million shares related to the Company's convertible notes due in April 2017.  The calculation of non-GAAP diluted earnings per share for the third quarter of 2009 includes the March 2013 notes reflecting 10.4 million shares.  The remaining periods presented exclude the 26.3 million shares related to the outstanding convertible debt from the non-GAAP diluted earnings per share calculation as their impact is considered anti-dilutive.

Conference Call DetailsBioMarin will host a conference call and webcast to discuss third quarter 2010 financial results today, Thursday, October 28, at 5:00 p.m. ET. This event can be accessed on the investor section of the BioMarin website at www.BMRN.com.

Date: October 28, 2010Time: 5:00 p.m. ET U.S. / Canada Dial-in Number:  866.202.3048International Dial-in Number:  617.213.8843Participant Code: 60493555Replay Dial-in Number: 888.286.8010Replay International Dial-in Number: 617.801.6888Replay Code: 45911037About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. BioMarin to Host a Research and Development Day on October 19th
2. BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
3. BioMarin to Present at the UBS Global Life Sciences Conference
4. BioMarin to Present at the Stifel Nicolaus Healthcare Conference
5. BioMarin Receives Orphan Drug Designation from the FDA for BMN-701 for the Treatment of Pompe Disease
6. BioMarin Acquires ZyStor Therapeutics, Inc.
7. BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU
8. BioMarin to Acquire LEAD Therapeutics
9. BioMarin to Present at the Credit Suisse Healthcare Conference
10. BioMarin Announces Third Quarter 2009 Financial Results
11. BioMarin to Present at the Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014  Decision Resources Group is launching an extension ... to now include ChinaTrack; the new capabilities track the ... interactive dashboard providing detailed brand-level share tracking and analytics. ... level. Other key capabilities of the new ... addition to end-user surveys of healthcare facilities, ChinaTrack data ...
(Date:7/31/2014)... Portugal , July 31, 2014 ... Cork, Ireland has successfully passed a pre-approval inspection ... The inspection, carried out by the FDA Consumer Safety Officer, ... planned, started on 21 st July and concluded on ... be compliant with the principles and guidelines of Good Manufacturing ...
(Date:7/31/2014)... VIENNA , July 31, 2014 ... in New York results of AFF008, ... Parkinson,s disease. PD01A is the first therapy against the protein ... The Michael J. Fox Foundation for Parkinson,s Research ... and presented at the press conference on the impact a ...
Breaking Medicine Technology:Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4
... Mich., Feb. 1, 2011 Fiscal second quarter ... million Fiscal second quarter GAAP income from continuing ... per share Fiscal second quarter adjusted income from ... Record second quarter cash flow from operations of ...
... Nephros, Inc. (OTC Bulletin Board: NEPH ), ... for therapeutic applications, infection control, and water purification, today ... its previously announced rights offering to its existing stockholders ... Securities and Exchange Commission. Under the terms ...
Cached Medicine Technology:Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 2Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 3Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 4Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 5Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 6Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 7Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 8Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 9Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 10Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 11Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 12Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 13Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 14Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 15Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 16Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 17Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 18Nephros Rights Offering Registration Statement Declared Effective 2Nephros Rights Offering Registration Statement Declared Effective 3Nephros Rights Offering Registration Statement Declared Effective 4
(Date:7/31/2014)... July 31, 2014 Joseph M. Lee, ... Hudson Valley (CDHV), a leading provider of quality cardiovascular ... Hudson Valley. Dr. Lee is a board certified ... , In addition to his position at CDHV, ... New York-Presbyterian Hospital/ Columbia University Medical Center. Dr. Lee ...
(Date:7/31/2014)... Bedford Commons OB-GYN partnered with local growth ... to do what Christina Haag, the practice administrator referred ... all while still offering the greatest service to our ... health needs for every stage of their life – ... Gynecology ), worked diligently with their marketing and strategy ...
(Date:7/31/2014)... 31, 2014 Transvaginal mesh lawsuits ( ... move forward in the federal multidistrict litigation underway in ... Liebhard LLP reports. According to an Order dated July ... defense motions now pending before the Court. The telephonic ... on Tuesday, August 5th at 2:30 p.m. (In re: ...
(Date:7/31/2014)... Live To Be Sober , a no-cost 24/7 ... and program information to people who want to help ... alcohol addiction, proudly announced today that it has entered ... bad boy, gone good. , "NBC's The Voice touched ... whose new single Stomp (#Stomp; available on iTunes ...
(Date:7/31/2014)... London, UK (PRWEB) July 31, 2014 ... in the development and maintenance of products in the ... can be performed by using various products and equipment ... and spoilage of various materials and products. , ... and services is forecast to post a CAGR of ...
Breaking Medicine News(10 mins):Health News:ColumbiaDoctors of the Hudson Valley Welcomes Joseph M. Lee, M.D., M.S., R.P.V.I. 2Health News:ColumbiaDoctors of the Hudson Valley Welcomes Joseph M. Lee, M.D., M.S., R.P.V.I. 3Health News:Doctor Videos & Women’s Stories Jumpstart Local OB-GYN Practice 2Health News:Doctor Videos & Women’s Stories Jumpstart Local OB-GYN Practice 3Health News:Doctor Videos & Women’s Stories Jumpstart Local OB-GYN Practice 4Health News:Ethicon Transvaginal Mesh Lawsuits Move Forward, With Scheduling of Hearing in Federal Litigation, Bernstein Liebhard LLP Reports 2Health News:Ethicon Transvaginal Mesh Lawsuits Move Forward, With Scheduling of Hearing in Federal Litigation, Bernstein Liebhard LLP Reports 3Health News:Addiction Referral Service Live To Be Sober (LiveToBeSober.com) Announces Sponsorship of Jared Blake: Country Music’s Bad Boy, Gone Good 2Health News:Addiction Referral Service Live To Be Sober (LiveToBeSober.com) Announces Sponsorship of Jared Blake: Country Music’s Bad Boy, Gone Good 3Health News:Infection Prevention and Control Market to Post about 7.5% CAGR through 2018, States Infiniti Research in Its Study Published at MarketPublishers.com 2Health News:Infection Prevention and Control Market to Post about 7.5% CAGR through 2018, States Infiniti Research in Its Study Published at MarketPublishers.com 3
... Inc. today will present Phase II clinical data ... next-generation antidepressant, is effective for treating major depressive ... outcome for depression. EB-1010 also improved measures of ... characterized by the inability to experience pleasure. The ...
... , TUESDAY, Dec. 7 (HealthDay News) -- Electronic cigarettes ... University of California researchers say. Their study ... devices that contain nicotine, flavorings and other chemicals. The ... and Drug Administration cited five e-cigarette distributors for poor ...
... pioneering clinical trial is testing the effectiveness in leukemia of ... can disable the well-known tumor suppressor p53. Michael ... Hematology and Therapy in the Department of Leukemia at The ... of this ongoing Phase I study at the 52nd Annual ...
... Madonna Behen HealthDay Reporter , TUESDAY, Dec. ... who suffer concussions may have different symptoms than boys, ... boys are more likely to report amnesia and confusion/disorientation, ... to noise more often. "The take-home message is ...
... A school-based intervention program designed for adolescents with ... life for the students who participate, and reduces ... City, who studied the effect of the program ... The Asthma Self-Management for Adolescents (ASMA) program is ...
... HealthDay Reporter , TUESDAY, Dec. 7 (HealthDay News) -- ... folks because they create a network of close friends ... Conducted at the University of Wisconsin, the researchers found ... say they are "extremely satisfied" with life as opposed ...
Cached Medicine News:Health News:Euthymics presents phase II data for EB-1010 in major depression at ACNP annual meeting 2Health News:Euthymics presents phase II data for EB-1010 in major depression at ACNP annual meeting 3Health News:E-Cigarettes Should Be Banned Until Made Safe: Study 2Health News:Small molecule may disarm enemy of cancer-fighting p53 2Health News:Concussion Symptoms Can Differ for Boys and Girls 2Health News:Concussion Symptoms Can Differ for Boys and Girls 3Health News:School-based program helps adolescents cope with asthma 2Health News:School-based program helps adolescents cope with asthma 3Health News:Friends May Be Key to Churchgoers' Happiness 2Health News:Friends May Be Key to Churchgoers' Happiness 3
... Premier Anterior Cervical Plate System allows ... translation along slots in the plate, ... distal end of the construct. In ... graft pre-compression features that enable the ...
... Cervive is an Anterior Cervical Plating ... provide flexibility and simplicity for the ... anatomical function and safe fixation of ... that meet the needs of the ...
... plate acc. to Matzen is used for ... (HWS) with the exception of C0-C2. The ... fusion length until the bone transplant has ... the vertebral bodies, if possible along the ...
The Codman anterior cervical plate is designed for immediate internal fixation of the cervical spine following bone grafting procedures....
Medicine Products: